Vaccine

A vaccine constitutes a biological preparation designed to confer active acquired immunity against specific infectious or malignant diseases. Extensive research has consistently affirmed the safety and efficacy of vaccines. Typically, a vaccine incorporates an agent mimicking a pathogenic microorganism, often derived from attenuated or inactivated forms of the microbe, its associated toxins, or specific surface proteins. This agent prompts the immune system to identify it as a potential threat, neutralize it, and subsequently develop a memory response to effectively recognize and eliminate any future encounters with microorganisms linked to that agent.

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. The safety and effectiveness of vaccines has been widely studied and verified. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the immune system to recognize the agent as a threat, destroy it, and recognize further and destroy any of the microorganisms associated with that agent that it may encounter in the future.

Vaccines serve either prophylactic purposes, aiming to prevent or mitigate the impact of future infections by natural or "wild" pathogens, or therapeutic functions, addressing existing diseases like cancer. Certain vaccines confer complete sterilizing immunity, thereby precluding infection entirely.

The process of administering vaccines is termed vaccination. Vaccination stands as the most efficacious strategy for preventing infectious diseases; the global eradication of smallpox and the significant reduction of diseases like polio, measles, and tetanus across numerous regions are primarily attributable to widespread vaccination efforts. The World Health Organization (WHO) indicates that licensed vaccines are currently accessible for twenty-five distinct preventable infections.

The earliest documented application of inoculation for smallpox prevention emerged in 16th-century China, with preliminary indications of this practice dating back to the 10th century within the same country. Smallpox also represents the inaugural disease for which a vaccine was developed. Lady Mary Wortley Montagu introduced the traditional practice of smallpox inoculation from Turkey to Britain in 1721. The nomenclature vaccine and vaccination originates from Variolae vaccinae (smallpox of the cow), a term coined by Edward Jenner—who conceptualized and created the first vaccine—to refer to cowpox. Jenner employed this phrase in 1798 for the comprehensive title of his work, Inquiry into the Variolae vaccinae Known as the Cow Pox, wherein he detailed the protective efficacy of cowpox against smallpox. In 1881, Louis Pasteur suggested expanding these terms to encompass emerging protective inoculations, thereby honoring Jenner's contributions. The scientific discipline dedicated to the development and manufacturing of vaccines is designated as vaccinology.

Efficacy

A predominant scientific consensus affirms that vaccines represent a highly safe and effective strategy for combating and eradicating infectious diseases. The immune system identifies vaccine components as foreign entities, subsequently eliminating them and retaining immunological memory. Upon encountering a virulent form of the pathogen, the body's immune response is primed to recognize its protein coat, enabling a rapid counteraction: initially, by neutralizing the target agent prior to cellular entry, and subsequently, by identifying and destroying infected cells before extensive replication of the agent can occur.

In 1958, the United States recorded 763,094 measles cases, resulting in 552 fatalities. Following the introduction of novel vaccines, the annual incidence of cases significantly decreased to fewer than 150, with a median of 56. By early 2008, 64 suspected measles cases were identified. Of these, 54 infections were linked to international importation, though only thirteen percent were definitively contracted outside the United States. Remarkably, 63 out of the 64 affected individuals either lacked prior measles vaccination or possessed uncertain vaccination status.

The measles vaccine is estimated to avert approximately one million deaths annually.

Vaccination campaigns were instrumental in achieving the eradication of smallpox, historically one of the most virulent and lethal human diseases. Furthermore, widespread immunization initiatives have dramatically reduced the prevalence of other diseases, including rubella, polio, measles, mumps, chickenpox, and typhoid, to levels significantly lower than those observed a century ago. When a substantial proportion of the population is vaccinated, the likelihood of disease outbreaks and subsequent transmission is considerably diminished; this phenomenon is known as herd immunity. Polio, a disease exclusively transmitted among humans, is the focus of an extensive eradication effort that has confined endemic polio to specific regions within three nations: Afghanistan, Nigeria, and Pakistan. Nevertheless, challenges such as difficulties in reaching all children, cultural misinterpretations, and the dissemination of misinformation have repeatedly delayed the projected eradication timeline.

Vaccination plays a crucial role in mitigating the emergence of antibiotic resistance. For instance, by substantially decreasing the occurrence of pneumonia attributed to Streptococcus pneumoniae, immunization initiatives have significantly lowered the prevalence of infections exhibiting resistance to penicillin and other primary antibiotics.

Limitations of Vaccine Efficacy

Despite their benefits, vaccines are subject to certain limitations regarding their effectiveness. Protective failures can arise from vaccine-specific factors, including inadequate attenuation, suboptimal vaccination regimens, or improper administration.

Furthermore, vaccine failure can stem from host-related factors, particularly when an individual's immune system exhibits an inadequate or absent response. This host-dependent non-response is observed in approximately 2–10% of individuals, influenced by elements such as genetics, immune status, age, overall health, and nutritional condition. A notable example of a primary immunodeficiency disorder leading to genetic failure is X-linked agammaglobulinemia, where the lack of an enzyme vital for B cell maturation precludes the host's immune system from producing antibodies against specific pathogens.

Host-pathogen interactions and the subsequent immune responses are dynamic processes engaging multiple immunological pathways. Antibody development is not instantaneous; while innate immunity can be activated within approximately twelve hours, the full development of adaptive immunity typically requires one to two weeks. Consequently, individuals remain susceptible to infection during this developmental period.

Upon antibody production, immunity can be conferred through various mechanisms, contingent upon the specific antibody class. The efficacy of these antibodies in clearing or inactivating a pathogen is determined by both the quantity generated and their effectiveness against the particular pathogen strain, given that different strains may exhibit varying susceptibilities to a specific immune response. In certain scenarios, vaccines may induce partial immune protection, where efficacy is less than 100% but still diminishes infection risk, or temporary immune protection, where immunity diminishes over time, rather than conferring complete or permanent immunity. Nevertheless, such protection can elevate the population's reinfection threshold and yield significant public health benefits. Furthermore, vaccines can attenuate infection severity, leading to reduced mortality rates, decreased morbidity, accelerated recovery, and a spectrum of other advantageous outcomes.

Elderly individuals frequently exhibit a diminished immune response compared to younger populations, a phenomenon termed immunosenescence. Adjuvants are routinely employed to enhance immune responses, especially in older adults whose immunological reactivity to conventional vaccines may be compromised.

Vaccine efficacy and performance are contingent upon several factors:

• The inherent characteristics of the disease, as vaccine effectiveness varies across different pathologies.
• The specific vaccine strain, given that certain vaccines are highly specific or most effective against particular disease variants.
• Adherence to the prescribed vaccination schedule.
• Idiosyncratic individual responses to vaccination, including instances of "non-responders" who fail to produce antibodies despite correct immunization.
• Diverse host-specific factors, including ethnicity, age, and genetic predisposition.

In cases where a vaccinated individual contracts the targeted disease (a breakthrough infection), the illness typically manifests with reduced severity and diminished transmissibility compared to infections in unvaccinated individuals.

Key considerations for establishing an effective vaccination program include:

1. Thorough epidemiological modeling to forecast the medium- to long-term impact of immunization campaigns on disease prevalence and transmission dynamics.
2. Continuous surveillance of the target disease subsequent to the introduction of a novel vaccine.
3. Sustaining high immunization coverage rates, even in scenarios where the disease incidence has become infrequent.

Vaccine Safety Profile

Vaccinations administered to pediatric, adolescent, and adult populations are typically considered safe. Any adverse effects are generally mild. The incidence of side effects varies depending on the specific vaccine. Common reactions may include fever, localized pain at the injection site, and myalgia. Furthermore, certain individuals may exhibit allergic reactions to vaccine components. The measles, mumps, and rubella (MMR) vaccine is infrequently linked to febrile seizures.

Vaccinee-related determinants, such as genetics, health status (including underlying disease, nutritional status, pregnancy, sensitivities, or allergies), immune competence, age, economic impact, and cultural environment, can serve as primary or secondary factors influencing infection severity and vaccine efficacy. Individuals over 60, those with allergen hypersensitivity, and obese populations often exhibit compromised immunogenicity, which can impede vaccine effectiveness. This may necessitate the development of distinct vaccine technologies or the administration of repeated booster vaccinations for these particular demographics to effectively mitigate virus transmission.

The occurrence of severe adverse effects is exceedingly uncommon. Complications linked to the varicella vaccine are infrequent among immunocompromised individuals, while rotavirus vaccines demonstrate a moderate association with intussusception.

A minimum of 19 nations have established no-fault compensation schemes to provide redress for individuals experiencing severe adverse effects from vaccination. In the United States, this initiative is designated as the National Childhood Vaccine Injury Act. Conversely, the United Kingdom utilizes the Vaccine Damage Payment.

Types

Vaccines generally comprise attenuated, inactivated, or defunct microorganisms, or purified components extracted from them. Currently, various vaccine classifications are employed. These categories reflect diverse strategic approaches aimed at mitigating disease risk while simultaneously eliciting a protective immune response.

Attenuated

Certain vaccines incorporate live, attenuated microorganisms. A significant number of these are active viruses cultured under conditions that diminish their virulence, or they utilize closely related, less pathogenic organisms to stimulate a comprehensive immune response. While the majority of attenuated vaccines are viral, a subset is bacterial. Illustrative examples encompass the viral pathologies of yellow fever, measles, mumps, and rubella, alongside the bacterial infection of typhoid. The live Mycobacterium tuberculosis vaccine, developed by Calmette and Guérin, does not employ a contagious strain; instead, it comprises a virulently modified strain known as "BCG," which is utilized to induce an immune response. For plague immunization, a live attenuated vaccine containing the Yersinia pestis EV strain is employed. Attenuated vaccines present both advantages and disadvantages. Live, weakened, or attenuated vaccines generally elicit more enduring immunological responses. Furthermore, attenuated vaccines stimulate both cellular and humoral immune responses. Nevertheless, their administration may be contraindicated for immunocompromised individuals, and in rare instances, they can revert to a virulent form, thereby causing disease.

Inactivated

Certain vaccines incorporate microorganisms that have been rendered inert or devitalized through physical or chemical processes. Illustrative examples include the Inactivated Polio Vaccine (IPV), hepatitis A vaccine, rabies vaccine, and the majority of influenza vaccines.

Toxoid

Toxoid vaccines are formulated from inactivated toxic compounds, which are responsible for disease pathogenesis, rather than from the microorganisms themselves. Notable examples of toxoid-based vaccines encompass those for tetanus and diphtheria. It is important to note that not all toxoids target microorganisms; for instance, the Crotalus atrox toxoid is administered to dogs to confer protection against rattlesnake envenomation.

Subunit

Instead of presenting an inactivated or attenuated microorganism to the immune system (a strategy characteristic of "whole-agent" vaccines), a subunit vaccine employs a specific fragment of the pathogen to elicit an immune response. A prime illustration is the subunit vaccine targeting hepatitisB, which consists solely of the virus's surface proteins (historically isolated from the blood serum of chronically infected individuals, but now generated through the recombination of viral genes into yeast). Further examples include the Gardasil virus-like particle human papillomavirus (HPV) vaccine, the hemagglutinin and neuraminidase subunits derived from the influenza virus, and innovative edible algae vaccines. Presently, a subunit vaccine is also utilized for plague immunization.

Conjugate

Some bacterial species possess a polysaccharide outer capsule that exhibits low immunogenicity. By covalently attaching these capsular polysaccharides to carrier proteins (such as toxins), the immune system can be induced to recognize the polysaccharide as a protein antigen. This methodology is applied in the Haemophilus influenzae type B vaccine.

Outer membrane vesicle

Outer membrane vesicles (OMVs) inherently possess immunogenic properties and can be engineered to yield highly effective vaccines. The most recognized OMV vaccines are those specifically formulated for serotype B meningococcal disease.

Heterotypic

Heterologous vaccines, also referred to as "Jennerian vaccines," utilize pathogens derived from other animal species that typically induce either no disease or only mild symptoms in the vaccinated organism. A historical illustration is Edward Jenner's application of cowpox to confer immunity against smallpox. A contemporary instance involves the administration of the BCG vaccine, formulated from Mycobacterium bovis, to provide protection against tuberculosis.

Genetic vaccine

Genetic vaccines operate on the principle of cellular uptake of nucleic acids, which subsequently direct the synthesis of a specific protein based on the nucleic acid template. This synthesized protein commonly functions as the pathogen's immunodominant antigen or a surface protein capable of eliciting neutralizing antibodies. Subcategories of genetic vaccines include viral vector vaccines, RNA vaccines, and DNA vaccines.

Viral vector

Viral vector vaccines employ an attenuated or non-pathogenic virus to introduce pathogen-specific genes into the host organism. These genes then direct the production of particular antigens, such as surface proteins, thereby eliciting an immune response. Viruses currently under investigation for their utility as viral vectors encompass adenovirus, vaccinia virus, and vesicular stomatitis virus (VSV).

RNA

An mRNA vaccine, also known as an RNA vaccine, represents an innovative vaccine modality comprising messenger RNA (mRNA) encapsulated within a delivery vehicle, such as lipid nanoparticles. Several RNA vaccines have been developed to address the COVID-19 pandemic, with some having attained regulatory approval or emergency use authorization in various nations. For instance, the Pfizer-BioNTech and Moderna mRNA vaccines are authorized for administration to adults and children within the United States.

DNA

A DNA vaccine utilizes a DNA plasmid (pDNA) that carries genetic instructions for an antigenic protein derived from the target pathogen. Plasmid DNA is characterized by its affordability, stability, and comparative safety profile, rendering it a highly suitable platform for vaccine delivery.

This methodology presents several prospective benefits compared to conventional vaccination strategies. These advantages include the induction of both B-cell and T-cell mediated immune responses, enhanced vaccine stability, the complete absence of infectious agents, and a relatively straightforward process for large-scale production.

Experimental

Numerous innovative vaccine candidates are currently undergoing development and implementation.

• Dendritic cell vaccines involve the ex vivo combination of dendritic cells with specific antigens, which are subsequently presented to the body's leukocytes, thereby initiating an immune response. Preliminary findings indicate promising outcomes for these vaccines in the treatment of brain tumors, and they are also being evaluated for melanoma.
• Recombinant vector vaccines leverage the physiological characteristics of one microorganism combined with the genetic material of another to confer immunity against diseases characterized by intricate infection mechanisms. An illustrative example is the RVSV-ZEBOV vaccine, licensed to Merck, which was deployed in 2018 to address the Ebola outbreak in the Democratic Republic of Congo.
• T-cell receptor peptide vaccines are currently under investigation for various diseases, utilizing models such as Valley Fever, stomatitis, and atopic dermatitis. Research indicates that these peptides can modulate cytokine production and enhance cell-mediated immunity.
• The strategic targeting of specific bacterial proteins implicated in complement inhibition could effectively neutralize a critical bacterial virulence mechanism.
• Plasmid utilization has been substantiated in preclinical investigations as a viable protective vaccine strategy for both cancer and infectious diseases. Nevertheless, human clinical trials have not demonstrated a clinically significant benefit from this approach. The ultimate efficacy of plasmid DNA immunization is contingent upon enhancing the plasmid's immunogenicity while simultaneously addressing factors crucial for the precise activation of immune effector cells.
• Bacterial vector vaccines operate on a principle analogous to viral vector vaccines, but they employ bacteria as the delivery vehicle.
• Antigen-presenting cell
• Technologies facilitating the swift deployment of vaccines in response to emerging pathogens encompass the application of virus-like particles or protein nanoparticles.
• Inverse vaccines are designed to instruct the immune system to suppress its response to specific substances.

In contrast to most vaccines, which are formulated from inactivated or attenuated microbial components, synthetic vaccines are predominantly or entirely composed of synthetically produced peptides, carbohydrates, or antigens.

Valence

Vaccines are categorized as either monovalent (also known as univalent) or multivalent (alternatively termed polyvalent). A monovalent vaccine is formulated to induce immunity against a singular antigen or a specific microorganism. Conversely, a multivalent or polyvalent vaccine is designed to confer immunity against two or more strains of the same microorganism, or against multiple distinct microorganisms. The valency of a multivalent vaccine is often indicated by a Greek or Latin prefix, such as bivalent, trivalent, or tetravalent/quadrivalent. In certain contexts, a monovalent vaccine may be preferred for eliciting a rapid and robust immune response.

Interactions

When multiple vaccines are combined within a single formulation, interference between the vaccine components can occur. This interaction is most frequently observed with live attenuated vaccines, where one component may exhibit greater robustness, thereby suppressing the growth and subsequent immune response to other constituents.

This phenomenon was documented in the trivalent Sabin polio vaccine, where the proportion of serotype2 virus required reduction to prevent its interference with the effective uptake of serotype1 and3 viruses within the vaccine. To achieve this, the dosages of serotypes1 and3 were increased in the vaccine during the early 1960s. A 2001 study also identified this issue in dengue vaccines, noting that the DEN-3 serotype predominated and suppressed the immune responses to DEN-1, -2, and -4 serotypes.

Other Components

Adjuvants

Vaccines typically incorporate one or more adjuvants, which are substances utilized to enhance the immune response. Tetanus toxoid, for example, is commonly adsorbed onto alum. This presentation method optimizes antigen delivery, resulting in a more potent immunological action compared to simple aqueous tetanus toxoid. Individuals who experience an adverse reaction to adsorbed tetanus toxoid may receive the unadsorbed vaccine when a booster dose is required.

During the preparation for the 1990 Persian Gulf campaign, the whole-cell pertussis vaccine was employed as an adjuvant for the anthrax vaccine. This combination elicits a more rapid immune response than administering the anthrax vaccine alone, which offers a significant advantage if potential exposure is imminent.

Preservatives

Vaccines may also contain preservatives to inhibit contamination by bacteria or fungi. Until recent years, the preservative thiomersal (a.k.a. Thimerosal in the US and Japan) was widely used in many vaccines that did not contain live viruses. As of 2005, the only childhood vaccine in the U.S. containing thiomersal in quantities exceeding trace amounts is the influenza vaccine, which is currently recommended solely for children with specific risk factors. Single-dose influenza vaccines supplied in the UK do not list thiomersal among their ingredients. Preservatives may be utilized at various stages of vaccine production, and even the most advanced measurement techniques might detect trace amounts in the final product, similar to their presence in the general environment and population.

Many vaccines necessitate preservatives to avert severe adverse effects, such as Staphylococcus infection, which, in a 1928 incident, resulted in the deaths of 12 out of 21 children inoculated with a diphtheria vaccine lacking a preservative. Several preservatives are available, including thiomersal, phenoxyethanol, and formaldehyde. Thiomersal demonstrates superior efficacy against bacteria, possesses a longer shelf-life, and enhances vaccine stability, potency, and safety. However, in the U.S., the European Union, and several other affluent nations, it is no longer incorporated as a preservative in childhood vaccines, a precautionary measure attributed to its mercury content. While controversial assertions have linked thiomersal to autism, no compelling scientific evidence supports these claims. Furthermore, a 10–11-year study involving 657,461 children concluded that the MMR vaccine does not cause autism and, in fact, reduced the risk of autism by seven percent.

Excipients

In addition to the active vaccine component itself, the following excipients and residual manufacturing compounds are present or may be present in vaccine preparations:

• Aluminum salts or gels are incorporated as adjuvants. Adjuvants are added to promote an earlier, more potent, and more persistent immune response to the vaccine, thereby allowing for a reduced vaccine dosage.
• Antibiotics are included in some vaccines to prevent bacterial growth during the production and storage phases of the vaccine.
• Influenza and yellow fever vaccines contain egg protein because their production involves the use of chicken eggs. Additional proteins may also be incorporated.
• Formaldehyde serves as an inactivating agent for bacterial products in the manufacturing of toxoid vaccines. Furthermore, it is employed to neutralize undesirable viruses and eradicate potential bacterial contaminants during the vaccine production process.
• In certain vaccines, monosodium glutamate (MSG) and 2-phenoxyethanol function as stabilizers, preserving the vaccine's integrity when subjected to environmental stressors such as heat, light, acidity, or humidity.
• Thiomersal, a mercury-containing antimicrobial, is incorporated into multi-dose vaccine vials to inhibit contamination and the proliferation of potentially deleterious bacteria. However, owing to ongoing controversies regarding thiomersal, its use has been largely discontinued in most vaccines, with the exception of multi-use influenza formulations. In these, its concentration has been lowered such that a single dose contains less than one microgram of mercury, an amount comparable to that found in ten grams of canned tuna.

Nomenclature

A range of relatively standardized abbreviations for vaccine names has emerged, though this standardization is neither centralized nor universally adopted. For instance, vaccine nomenclature employed within the United States features well-established abbreviations that are also recognized and utilized internationally. An extensive, sortable, and freely accessible compilation of these abbreviations is available on a webpage from the U.S. Centers for Disease Control and Prevention. This resource clarifies that "The abbreviations [in] this table (Column 3) were standardized jointly by staff of the Centers for Disease Control and Prevention, ACIP Work Groups, the editor of the Morbidity and Mortality Weekly Report (MMWR), the editor of Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book), ACIP members, and liaison organizations to the ACIP."

Illustrative examples include "DTaP" for diphtheria and tetanus toxoids and acellular pertussis vaccine, "DT" for diphtheria and tetanus toxoids, and "Td" for tetanus and diphtheria toxoids. The CDC, on its resource concerning tetanus vaccination, further elucidates that "Upper-case letters in these abbreviations denote full-strength doses of diphtheria (D) and tetanus (T) toxoids and pertussis (P) vaccine. Lower-case "d" and "p" denote reduced doses of diphtheria and pertussis used in the adolescent/adult-formulations. The 'a' in DTaP and Tdap stands for 'acellular', meaning that the pertussis component contains only a part of the pertussis organism."

An additional compilation of established vaccine abbreviations, specifically those utilized on U.S. immunization records, is available from the CDC's resource titled "Vaccine Acronyms and Abbreviations." The United States Adopted Name (USAN) system employs specific conventions for vaccine name word order, prioritizing head nouns and placing adjectives postpositively. Consequently, the USAN designation for "OPV" is "poliovirus vaccine live oral," as opposed to "oral poliovirus vaccine."

Licensing

The licensure of a vaccine is granted subsequent to the successful completion of its development cycle, encompassing clinical trials and associated programs across PhasesI–III. These phases must rigorously demonstrate safety, immunoactivity, immunogenetic safety at a specified dose, confirmed efficacy in preventing infection within target populations, and a sustained preventive effect (requiring estimation of duration or need for revaccination). Given that preventive vaccines are primarily assessed in healthy population cohorts and disseminated throughout the general populace, an exceptionally stringent safety standard is mandated. For multinational vaccine licensing, the World Health Organization's Expert Committee on Biological Standardization has established guidelines for international standards in vaccine manufacturing and quality control. This framework serves as a foundation for national regulatory agencies to implement their respective licensing procedures. Vaccine manufacturers are not granted licensing until a comprehensive clinical development and trial cycle conclusively establishes the vaccine's safety and long-term effectiveness, following a thorough scientific review by a multinational or national regulatory body, such as the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA).

Following the adoption by developing nations of WHO guidelines for vaccine development and licensure, each nation assumes responsibility for issuing national licensure, as well as for managing, deploying, and monitoring the vaccine throughout its period of use. Establishing public trust and acceptance for a licensed vaccine necessitates effective communication strategies from governments and healthcare professionals to facilitate smooth vaccination campaign execution, preserve lives, and foster economic recuperation. Post-licensure, a vaccine typically faces initial supply constraints attributable to manufacturing variability, distribution challenges, and logistical complexities, thereby necessitating a strategic allocation plan to prioritize specific population segments for initial inoculation.

World Health Organization

Vaccines intended for multinational distribution through the United Nations Children's Fund (UNICEF) must undergo pre-qualification by the WHO. This process ensures adherence to international benchmarks for quality, safety, immunogenicity, and efficacy, facilitating their adoption across multiple nations.

This process mandates consistent manufacturing practices in WHO-contracted laboratories, adhering to Good Manufacturing Practice (GMP) guidelines. In instances where UN agencies participate in vaccine licensure, individual nations contribute by (1) granting marketing authorization and a national license for the vaccine, its manufacturers, and distribution partners, and (2) implementing post-marketing surveillance, which encompasses the documentation of adverse events following the vaccination program. The WHO collaborates with national agencies to oversee inspections of manufacturing facilities and distributors, ensuring compliance with GMP and broader regulatory frameworks.

Certain nations opt to procure vaccines licensed by established national organizations, including the EMA, FDA, or equivalent agencies in other economically developed countries. However, these acquisitions generally incur higher costs and may lack distribution infrastructure appropriate for the specific local conditions prevalent in developing countries.

European Union

Within the European Union (EU), vaccines targeting pandemic pathogens, such as seasonal influenza, can be licensed through several pathways: EU-wide, requiring compliance from all member states (a 'centralized' approach); for a subset of member states (a 'decentralized' approach); or at an individual national level. Typically, all EU member states adhere to the regulatory guidance and clinical protocols established by the European Committee for Medicinal Products for Human Use (CHMP), a scientific panel within the European Medicines Agency (EMA) tasked with vaccine licensure. The CHMP receives support from various expert groups responsible for evaluating and overseeing a vaccine's development both pre- and post-licensure and distribution.

United States

The U.S. Food and Drug Administration (FDA) employs the same rigorous process for establishing clinical safety and efficacy evidence for vaccines as it does for the approval of prescription pharmaceuticals. Upon successful completion of clinical development stages, the vaccine licensure process culminates in a Biologics License Application. This application requires comprehensive documentation demonstrating the vaccine candidate's efficacy and safety throughout its development, reviewed by a multidisciplinary scientific team comprising experts such as physicians, statisticians, microbiologists, and chemists. Concurrently, expert reviewers inspect the proposed manufacturing facility for adherence to Good Manufacturing Practice (GMP). Furthermore, the vaccine's labeling must contain a compliant description, enabling healthcare providers to define its specific use, including potential risks, for effective communication and public administration. Post-licensure, continuous monitoring of the vaccine and its production, including regular GMP compliance inspections, persists as long as the manufacturer holds the license. This oversight may entail submitting additional data to the FDA regarding potency, safety, and purity tests for each stage of vaccine manufacturing.

India

In India, the Drugs Controller General, who leads the Central Drugs Standard Control Organization—the nation's regulatory authority for cosmetics, pharmaceuticals, and medical devices—is tasked with approving licenses for specific drug categories. These include vaccines and other medicinal products like blood or blood products, intravenous fluids, and sera.

Postmarketing surveillance

Until a vaccine achieves widespread public adoption, the full spectrum of potential adverse events may remain uncharacterized, necessitating manufacturers to undertake PhaseIV studies for post-marketing surveillance during extensive public use. The World Health Organization (WHO) collaborates with United Nations member states to establish and implement post-licensing surveillance protocols. In the United States, the Food and Drug Administration (FDA) utilizes a Vaccine Adverse Event Reporting System to continuously monitor vaccine safety concerns throughout their deployment within the American populace.

Vaccination Scheduling

To ensure optimal protection, children are advised to receive vaccinations promptly once their immune systems are adequately mature to elicit a response to specific vaccines. Achieving comprehensive immunity often necessitates supplementary "booster" doses, contributing to the development of intricate vaccination schedules. Global vaccination schedule recommendations are formulated by the Strategic Advisory Group of Experts, subsequently adapted by national advisory committees. These country-level adaptations consider various local factors, including disease epidemiology, public acceptance of vaccination, equity across local populations, and existing programmatic and financial limitations. Within the United States, the Advisory Committee on Immunization Practices (ACIP), which advises the Centers for Disease Control and Prevention (CDC) on schedule modifications, advocates for routine childhood immunization against hepatitis A, hepatitis B, polio, mumps, measles, rubella, diphtheria, pertussis, tetanus, Haemophilus influenzae type b (HiB), varicella (chickenpox), rotavirus, influenza, meningococcal disease, and pneumonia.

The substantial number of recommended vaccines and booster doses, potentially reaching 24 injections by the age of two, has presented challenges in achieving complete adherence to immunization schedules. To mitigate declining compliance rates, various notification systems have been implemented, and numerous combination vaccines, such as the Pentavalent vaccine and the MMRV vaccine, are now commercially available, offering protection against multiple diseases simultaneously.

Beyond the immunization schedules for infants and booster doses, numerous specific vaccines are advised for other age groups or require repeated administration throughout an individual's lifespan, commonly for measles, tetanus, influenza, and pneumonia. Pregnant women frequently undergo screening to ascertain sustained immunity to rubella. The human papillomavirus (HPV) vaccine has been recommended in the United States since 2011 and in the United Kingdom since 2009. Immunization guidelines for the elderly primarily focus on pneumonia and influenza, given their heightened mortality risk within this demographic. In 2006, a vaccine targeting shingles, a disease caused by the varicella-zoster virus (chickenpox virus) and predominantly affecting older adults, was introduced.

The scheduling and dosage of vaccinations can be customized based on an individual's immunocompetence. Furthermore, these parameters may be optimized for population-wide vaccine deployment, particularly when supply is constrained, such as during a pandemic.

Economic Aspects of Vaccine Development

A significant economic challenge in vaccine development stems from the fact that many diseases urgently requiring a vaccine, such as HIV, malaria, and tuberculosis, are predominantly prevalent in low-income nations. In contexts like the United States, the financial returns for vaccine development are typically modest, while the associated financial and other risks are substantial.

Historically, the majority of vaccine development has been sustained by "push" funding mechanisms, originating from governmental bodies, academic institutions, and non-profit organizations. Numerous vaccines have demonstrated high cost-effectiveness and significant public health benefits. The volume of vaccines administered has experienced a dramatic increase in recent decades. This surge, particularly concerning the diversity of vaccines given to children prior to school enrollment, is likely attributable to governmental mandates and support rather than purely economic incentives.

Vaccine Patents

According to the World Health Organization (WHO), the primary impediment to vaccine production in less developed nations has not been intellectual property patents. Instead, the most significant barriers are the considerable financial investments, infrastructural demands, and skilled workforce requirements essential for market entry. Vaccines are intricate biological formulations, and unlike conventional prescription pharmaceuticals, there are no genuine "generic" equivalents. Any vaccine manufactured by a new facility must undergo comprehensive clinical testing by the producer to confirm its safety and efficacy. While specific technological processes for most vaccines are patented, these can often be bypassed through the development of alternative manufacturing methodologies. However, such circumvention necessitates robust research and development (R&D) infrastructure and a proficient workforce. For a limited number of relatively novel vaccines, such as the human papillomavirus vaccine, patents may indeed present an additional obstacle.

In 2021, amidst the urgent demand for increased vaccine production during the COVID-19 pandemic, the World Trade Organization and various global governments assessed the feasibility of waiving intellectual property rights and patents for COVID-19 vaccines. Such a measure was posited to "eliminate all potential barriers to the timely access of affordable COVID-19 medical products, including vaccines and medicines, and scale up the manufacturing and supply of essential medical products."

Vaccine Production

Vaccine manufacturing diverges significantly from other production methodologies, including standard pharmaceutical processes, primarily because vaccines are designed for administration to millions of individuals, most of whom are in good health. This inherent characteristic necessitates an exceptionally rigorous production framework, incorporating stringent compliance mandates that considerably exceed those imposed on other products.

The establishment of a vaccine manufacturing facility can incur costs ranging from US$50 million to US$500 million, contingent on the specific antigen, and necessitates highly specialized equipment, along with dedicated clean rooms and containment areas. Furthermore, a global deficit exists in personnel possessing the requisite blend of skills, expertise, knowledge, competence, and disposition essential for operating vaccine production lines. Excluding Brazil, China, and India, educational systems in numerous developing nations frequently fail to generate a sufficient pool of qualified candidates, compelling vaccine manufacturers in these regions to employ expatriate staff to sustain operations.

Vaccine production encompasses multiple distinct stages, commencing with the generation of the antigen. Viruses are typically cultivated either on primary cells, such as chicken eggs (e.g., for influenza vaccines), or within continuous cell lines, like cultured human cells (e.g., for hepatitis A vaccines). Conversely, bacteria are propagated in bioreactors (e.g., Haemophilus influenzae type b). Additionally, recombinant proteins, derived from either viruses or bacteria, can be produced using yeast, bacterial cultures, or other cell cultures.

Subsequent to antigen generation, the antigen undergoes isolation from its host cells. Viral antigens may necessitate inactivation, potentially without further purification. In contrast, recombinant proteins typically require extensive purification processes, including ultrafiltration and column chromatography. The final stage involves vaccine formulation, wherein adjuvants, stabilizers, and preservatives are incorporated as required. Adjuvants serve to augment the immune response to the antigen, stabilizers extend the product's shelf life, and preservatives facilitate the use of multidose vials. The development and production of combination vaccines present greater challenges due to potential incompatibilities and interactions among the various antigens and other constituents.

The ultimate phase in vaccine manufacturing prior to distribution is termed 'fill and finish,' which encompasses the processes of dispensing vaccines into vials and subsequently packaging them for shipment. Despite its conceptual straightforwardness within the overall manufacturing sequence, this stage frequently constitutes a significant bottleneck in the broader distribution and administration of vaccines.

Vaccine production methodologies are continually advancing. Cultured mammalian cells are projected to gain increasing prominence over traditional substrates like chicken eggs, owing to their enhanced productivity and reduced susceptibility to contamination issues. Recombination technology, which facilitates the creation of genetically detoxified vaccines, is anticipated to become more prevalent for bacterial vaccines utilizing toxoids. Furthermore, combination vaccines are expected to incorporate reduced quantities of antigens, thereby mitigating undesirable interactions through the application of pathogen-associated molecular patterns.

Vaccine Manufacturers

The global vaccine market is dominated by major pharmaceutical companies, including Merck, Sanofi, GlaxoSmithKline, Pfizer, and Novartis, which collectively accounted for 70% of vaccine sales concentrated within the European Union and the United States in 2013. Establishing vaccine manufacturing facilities necessitates substantial capital investment, ranging from $50 million to $300 million, with construction periods typically spanning 4 to 6 years. The entire vaccine development process, from research to market, generally requires 10 to 15 years. Developing nations, particularly Brazil, India, and China, are increasingly contributing to the supply of vaccines, especially older formulations, within their respective regions. India's vaccine manufacturers are recognized as the most advanced among developing countries, exemplified by the Serum Institute of India. This institution is a leading global producer by dose volume and an innovator in manufacturing processes, having recently enhanced measles vaccine production efficiency by 10 to 20-fold through the adoption of MRC-5 cell culture instead of traditional chicken eggs. China's manufacturing sector, notably Sinopharm (CNPGC), primarily focuses on fulfilling domestic demand, supplying over 85% of the doses for 14 distinct vaccines within the country. Brazil is also progressing towards self-sufficiency in vaccine supply, leveraging technology transfer from more developed nations.

Vaccine Delivery Systems

Injection remains a predominant method for administering vaccines into the human body.

The ongoing development of novel vaccine delivery systems holds promise for enhancing both the safety and administrative efficiency of immunizations. Current research avenues encompass technologies such as liposomes and ISCOM (immune stimulating complex).

Oral Vaccine Formulations

Oral vaccines represent a significant advancement in vaccine delivery technologies. Initial efforts to develop oral vaccine formulations in the early 20th century yielded inconsistent results, particularly amidst skepticism regarding the feasibility of effective oral antibacterial vaccines. Nevertheless, by the 1930s, scientific interest in the prophylactic efficacy of oral vaccines, such as for typhoid fever, began to intensify.

The efficacy of an oral polio vaccine was notably demonstrated even when administered by volunteer personnel lacking formal medical training, highlighting its ease and efficiency of deployment. Effective oral vaccines offer several distinct advantages, including the elimination of blood contamination risks. Furthermore, oral vaccines can be formulated as solids, which typically exhibit greater stability and reduced susceptibility to damage or spoilage from freezing during transportation and storage. This enhanced stability mitigates the reliance on a "cold chain"—the logistical infrastructure necessary to maintain vaccines within a specific temperature range from production to administration—thereby potentially lowering overall vaccine costs.

Microneedle Vaccine Technology

The microneedle approach, currently undergoing developmental stages, involves arrays of pointed projections engineered to facilitate vaccine delivery pathways directly through the skin.

Dermal Patch Vaccines

An experimental needle-free vaccine delivery system, currently in animal testing phases, utilizes a stamp-sized dermal patch resembling an adhesive bandage. This patch incorporates approximately 20,000 microscopic projections per square centimeter. This method of dermal administration has the potential to enhance vaccination effectiveness while simultaneously reducing the required vaccine dosage compared to traditional injection.

Applications in Veterinary Medicine

Animal vaccinations serve a dual purpose: preventing disease contraction within animal populations and mitigating the transmission of zoonotic diseases to humans. Routine immunization protocols are established for both companion animals and livestock. Furthermore, vaccination efforts occasionally extend to wild animal populations, often through the distribution of vaccine-laced food in areas susceptible to disease outbreaks, a strategy notably employed in attempts to control rabies in raccoons.

In regions where rabies is endemic, canine rabies vaccination may be a legal prerequisite. Additional common canine immunizations target diseases such as canine distemper, canine parvovirus, infectious canine hepatitis, adenovirus-2, leptospirosis, Bordetella, canine parainfluenza virus, and Lyme disease, among others.

Instances of veterinary vaccines being administered to humans, either intentionally or inadvertently, have been recorded, occasionally leading to illness, particularly brucellosis. Nevertheless, the documentation of these occurrences is infrequent, and comprehensive research into the safety and outcomes of such applications remains limited. The introduction of aerosol vaccination methods in veterinary settings has probably contributed to a recent rise in human exposure to zoonotic pathogens, including Bordetella bronchiseptica, which are not typically found in human hosts. For certain pathogens, such as rabies, the corresponding veterinary vaccine can be substantially more cost-effective, by orders of magnitude, than its human counterpart.

DIVA Vaccines

DIVA (Differentiation of Infected from Vaccinated Animals) vaccines, alternatively termed SIVA (Segregation of Infected from Vaccinated Animals) vaccines, enable the distinction between animals that have been infected and those that have been vaccinated. These vaccines are engineered to lack at least one epitope present in the corresponding wild-type microorganism. A complementary diagnostic assay, designed to detect antibodies against this specific missing epitope, facilitates the determination of an animal's infection or vaccination status.

The initial DIVA vaccines, previously known as marker vaccines until their rebranding as DIVA vaccines in 1999, along with their associated diagnostic tests, were pioneered by J. T. van Oirschot and his research team at the Central Veterinary Institute in Lelystad, The Netherlands. Their investigations revealed that certain established vaccines targeting pseudorabies, also referred to as Aujeszky's disease, possessed deletions within their viral genome, specifically including the gE gene. Monoclonal antibodies were subsequently generated to target this deletion, and these were utilized to create an ELISA capable of detecting antibodies against gE. Furthermore, innovative gE-negative vaccines were engineered through genetic modification. Following a similar methodology, DIVA vaccines and their corresponding diagnostic assays have been formulated to combat bovine herpesvirus1 infections.

The DIVA strategy has been effectively implemented in multiple nations, leading to the successful eradication of pseudorabies virus within their borders. Swine populations underwent intensive vaccination and continuous monitoring via the associated diagnostic test, with infected animals subsequently culled from the herds. In practical applications, bovine herpesvirus1 DIVA vaccines are also extensively employed. Significant research and development initiatives are currently underway to extend the application of the DIVA principle to a broader spectrum of infectious diseases, including classical swine fever, avian influenza, Actinobacillus pleuropneumonia, and Salmonella infections in porcine populations.

History

Before the advent of vaccination utilizing cowpox material (heterotypic immunization), smallpox was preventable through intentional variolation with the smallpox virus. Historian Joseph Needham posited that Taoists in China engaged in a form of inoculation as early as the 10th century, transmitting this knowledge via oral tradition; however, Needham's assertion has faced criticism due to the absence of written records detailing the practice. The earliest documented application of variolation is also attributed to the Chinese, with records tracing back to the fifteenth century. This involved a technique known as 'nasal insufflation,' wherein powdered smallpox material, typically scabs, was blown into the nostrils. Diverse insufflation methodologies were documented across China during the sixteenth and seventeenth centuries. In 1700, the Royal Society in London received two accounts concerning the Chinese inoculation practice: one from Martin Lister, based on a report by an East India Company employee in China, and another from Clopton Havers. In France, Voltaire noted that the Chinese had been practicing variolation for 'these hundred years'.

Upon her return to England in 1721, Mary Wortley Montagu, having observed variolation in Turkey, arranged for her four-year-old daughter to undergo the procedure in the presence of Royal Court physicians. Later that same year, Charles Maitland performed an experimental variolation on six inmates at Newgate Prison in London. This experiment proved successful, quickly attracting the interest of the royal family, who subsequently endorsed the procedure. Nevertheless, in 1783, Prince Octavius of Great Britain succumbed to death several days following his inoculation.

In 1796, physician Edward Jenner conducted an experiment by extracting pus from a milkmaid afflicted with cowpox and inoculating an 8-year-old boy, James Phipps, with it. Six weeks later, Jenner exposed Phipps to smallpox, subsequently observing that the boy did not contract the disease. Expanding on these findings, Jenner published in 1798 that his vaccine was safe for both pediatric and adult populations and could be transmitted from person to person, thereby mitigating dependence on inconsistent supplies derived from infected cattle. By 1804, the Spanish Balmis smallpox vaccination expedition utilized this arm-to-arm transfer technique during its mission to Spain's colonies in Mexico and the Philippines, circumventing the challenge that the vaccine's viability was limited to 12 days in vitro. The expedition specifically employed cowpox. Given that cowpox vaccination presented significantly fewer risks than smallpox inoculation, the latter practice, despite its prevalence in England, was prohibited in 1840.

Building upon Jenner's foundational work, Louis Pasteur pioneered the second generation of vaccines in the 1880s, developing immunizations against chicken cholera and anthrax. From the late nineteenth century onward, vaccines gained recognition as a symbol of national prestige, leading to the implementation of national vaccination policies and the enactment of mandatory vaccination legislation. In 1931, Alice Miles Woodruff and Ernest Goodpasture demonstrated the successful cultivation of the fowlpox virus within embryonated chicken eggs. This discovery soon prompted scientists to propagate other viruses using eggs, a method instrumental in the creation of the yellow fever vaccine in 1935 and the influenza vaccine in 1945. By 1959, growth media and cell culture superseded eggs as the primary method for viral propagation in vaccine production.

The twentieth century marked a period of significant advancement in vaccinology, characterized by the introduction of numerous effective vaccines, such as those targeting diphtheria, measles, mumps, and rubella. Key milestones included the development of the polio vaccine in the 1950s and the global eradication of smallpox throughout the 1960s and 1970s. Maurice Hilleman distinguished himself as the most prolific vaccine developer of the twentieth century. Despite the increasing prevalence of vaccines, public appreciation for their impact sometimes diminished. Nevertheless, effective vaccines for several critical diseases, including herpes simplex, malaria, gonorrhea, and HIV, continue to be sought.

Vaccine Generations

First-generation vaccines comprise whole-organism preparations, existing either as live, attenuated forms or as inactivated (killed) forms. Live, attenuated vaccines, exemplified by those for smallpox and polio, are capable of eliciting robust killer T-cell (T_C or CTL) responses, helper T-cell (T_H) responses, and humoral immunity. However, attenuated pathogens carry the inherent risk of reverting to a virulent state, potentially causing disease in immunocompromised individuals, such as those with AIDS. Conversely, inactivated vaccines mitigate this risk but are unable to induce specific killer T-cell responses and may prove ineffective against certain diseases.

Second-generation vaccines were engineered to mitigate the risks associated with live vaccines. These subunit vaccines are composed of specific protein antigens, such as tetanus or diphtheria toxoids, or recombinant protein components, like the hepatitis B surface antigen. They effectively stimulate T_H and antibody responses but do not induce killer T-cell responses.

Third-generation vaccines encompass RNA and DNA vaccine platforms. In 2016, a DNA vaccine targeting the Zika virus commenced trials at the National Institutes of Health. Concurrently, Inovio Pharmaceuticals and GeneOne Life Science initiated separate trials for an alternative DNA vaccine against Zika in Miami. As of 2016, large-scale manufacturing of these vaccines remained an unresolved challenge. Clinical trials for DNA vaccines aimed at preventing HIV are currently in progress. mRNA vaccines, exemplified by BNT162b2, were developed in 2020 with support from Operation Warp Speed and were extensively deployed to address the COVID-19 pandemic. In 2021, Katalin Karikó and Drew Weissman were awarded Columbia University's Horwitz Prize for their groundbreaking contributions to mRNA vaccine technology.

Current Trends

Since at least 2013, researchers have focused on developing synthetic third-generation vaccines through the reconstruction of viral external structures, with the expectation that this approach could mitigate vaccine resistance.

Principles governing the immune response are now being applied to develop personalized vaccines for various non-infectious human diseases, including cancers and autoimmune conditions. For instance, the experimental vaccine CYT006-AngQb has been explored as a potential therapeutic agent for hypertension. Influencing factors in vaccine development trends encompass advancements in translational medicine, demographic shifts, regulatory science, and sociopolitical and cultural considerations.

Plants as Bioreactors in Vaccine Manufacturing

The concept of producing vaccines through transgenic plants emerged by 2003. Specific plant species, including tobacco, potato, tomato, and banana, can be genetically engineered to express vaccine components suitable for human administration. Notably, in 2005, bananas were engineered to produce a human vaccine targeting hepatitis B.

Vaccine Hesitancy

Vaccine hesitancy is defined as a reluctance or refusal to accept vaccination, even when immunization services are accessible. This phenomenon encompasses outright rejection of vaccines, delayed vaccination schedules, conditional acceptance with lingering doubts regarding efficacy or safety, or selective vaccination against specific diseases. An overwhelming scientific consensus affirms the general safety and efficacy of vaccines. Frequently, vaccine hesitancy contributes to outbreaks of vaccine-preventable diseases and associated fatalities. Consequently, the World Health Organization designated vaccine hesitancy as one of the top ten global health threats in 2019.

References

Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. (2021). Epidemiology and Prevention of Vaccine-Preventable Diseases (14th ed.). Washington D.C.: U.S. Centers for Disease Control and Prevention (CDC).

• Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. (2021). Epidemiology and Prevention of Vaccine-Preventable Diseases (14th ed.). Washington D.C.: U.S. Centers for Disease Control and Prevention (CDC).
  • Immunization, vaccine preventable diseases and polio transition World Health Organization
  • This website was highlighted by Genetic Engineering & Biotechnology News in its "Best of the Web" section in January 2015. "The History of Vaccines". Best of the Web. Genetic Engineering & Biotechnology News. Vol. 35, no. 2. 15 January 2015. p. 38.
  • The History of Vaccines, from the College of Physicians of Philadelphia

    This website was highlighted by Genetic Engineering & Biotechnology News in its "Best of the Web" section in January 2015. See: "The History of Vaccines". Best of the Web. Genetic Engineering & Biotechnology News. Vol. 35, no. 2. 15 January 2015. p. 38.